Tag: pharma operations

Addressing Gaps in Risk Management Plans During Post-Marketing Surveillance Pharmaceutical companies often face challenges with their risk management plans (RMPs), particularly during post-marketing surveillance. Gaps in RMPs can lead to…

Addressing PV System Audit Findings During Inspections to Prevent Recurrences Pharmaceutical organizations often face challenges related to audit findings during inspections of their Pharmacovigilance (PV) systems. These findings can signify…

Understanding and Addressing PV System Audit Findings During Benefit-Risk Assessment Pharmaceutical organizations rely heavily on Pharmacovigilance (PV) systems to ensure drug safety throughout the product lifecycle. Audit findings pertaining to…

Addressing Delays in Safety Signal Escalation during Benefit-Risk Assessments In the realm of pharmaceutical development and pharmacovigilance, the timely escalation of safety signals is paramount for effective benefit-risk assessment. Delays…

Addressing Delays in Safety Signal Escalation During Signal Review: Investigative Strategies In the highly regulated pharmaceutical landscape, timely and effective safety signal escalation is crucial to ensure patient safety and…

Addressing Literature Surveillance Failures During Regulatory Inspections During regulatory inspections, pharmaceutical companies may encounter significant challenges related to literature surveillance failures. These failures can manifest through inconsistent data, overlooked literature…